Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165490 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00165490 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT00165490, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG Irinotecan
- PROCEDURE Surgery
- DEVICE Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165490
The ClinicalTrials.gov registry entry for NCT00165490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00165490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165490 about?
NCT00165490 is a clinical study titled "Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer". The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.
What is the current status of trial NCT00165490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2004-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00165490?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), Irinotecan (DRUG), Surgery (PROCEDURE), Radiation therapy (DEVICE).
Who is sponsoring clinical trial NCT00165490?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.